Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

Movement Disorders - Tập 16 Số 3 - Trang 448-458 - 2001
J. Eric Ahlskog1, Manfred D. Muenter2
1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
2Department of Neurology, Mayo Clinic, Scottsdale, Arizona USA

Tóm tắt

AbstractThere is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (1) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series.We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa‐induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD‐onset well before levodopa availability (pre‐levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series.Among series containing pre‐levodopa era patients, the median dyskinesia frequency was already 50% by 5–6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4–6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing‐off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4–6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures.The conclusions reached were: (1) patients from the pre‐levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre‐existing PD; (2) in the present era, patients treated with levodopa therapy for 4–6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less. © 2001 Movement Disorder Society.

Từ khóa


Tài liệu tham khảo

Bedard PJ, 1999, Pathophysiology of l‐dopa‐induced dyskinesias, Mov Disord, 14, 4

Rascol O, 1999, L‐dopa‐induced peak‐dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach, Mov Disord, 14, 19

10.1212/WNL.50.3_Suppl_3.S1

10.1159/000117399

10.1001/jama.283.15.2008

10.1136/jnnp.49.4.390

Riopelle RJ, 1988, A double‐blind study of bromocriptine and l‐dopa in de novo Parkinson's disease, Eur Neurol, 28, 11

10.1002/mds.870130111

10.1002/ana.410220415

10.1212/WNL.35.8.1258

10.1002/ana.410390107

10.1001/jama.284.15.1931

10.1056/NEJM198402233100802

10.1002/mds.870020201

10.1212/WNL.41.2_Part_1.168

10.1212/WNL.41.2_Part_1.202

Pantelatos A, 1993, 690

10.1002/mds.870130605

10.1016/S0140-6736(69)91417-2

Mones RJ, 1969, A short‐term evaluation of L‐dopa therapy in 34 patients with parkinsonism, J Mount Sinai Hospital N Y, 36, 503

10.1016/S0140-6736(70)90002-4

10.1007/BF00316422

Yahr MD, 1970, L‐dopa and Parkinsonism, 101

10.1212/WNL.24.10.912

10.1016/0021-9681(74)90009-5

10.1159/000113990

10.1002/cpt1971122part2340

10.5694/j.1326-5377.1972.tb47582.x

10.1177/070674377201700207

10.1007/BF00312459

Yahr MD, 1968, L‐dopa (L‐3,4‐dihydroxyphenylanine)—its clinical effects in parkinsonism, Trans Am Neurol Assoc, 93, 56

Barbeau A, 1969, L‐dopa therapy in Parkinson's disease: a critical review of nine years’ experience, Can Med Assoc J, 101, 59

10.1016/S0140-6736(69)90536-4

10.1111/j.1600-0404.1976.tb04355.x

10.1001/archneur.1969.00480160015001

Hofmann WW, 1970, A controlled study of L‐DOPA in Parkinson's disease, Cal Med, 112, 9

10.1136/bmj.1.5692.331

10.7326/0003-4819-72-1-29

Reef HE, 1971, Treatment of severe parkinsonism with L‐dopa, South African Med J, 45, 504

10.1016/S0140-6736(71)91834-4

10.1136/jnnp.34.6.668

McFarland HR, 1971, Levodopa therapy for Parkinson's disease. A first‐year experience with outpatients in private practice, Missouri Med, 68, 843

10.1111/j.1600-0404.1974.tb02818.x

10.1007/BF03004744

Shaw KM, 1980, The impact of treatment with levodopa on Parkinson's disease, Quart J Med, 49, 283

10.1212/WNL.31.2.125

10.1212/WNL.34.8.991

Bergmann KJ, 1986, 463

10.1056/NEJM196907312810517

10.1212/WNL.20.12_Part_2.6

10.1212/WNL.20.12_Part_2.18

10.1002/cpt1971122part2353

Reveno WS, 1971, L‐dopa treatment of parkinsonism, Geriatrics, 26, 61

10.1007/BF02939866

10.1002/cpt1971122part2323

10.1001/jama.1971.03180380037008

10.7326/0003-4819-75-5-703

Lees AJ, 1983, 9

10.1212/WNL.35.8.1196

10.7326/0003-4819-83-4-456

10.1007/BF00314037

10.1002/ana.410370117

10.1212/WNL.48.2.363

Hoehn MMM, 1983, Parkinsonism treated wilth levodopa: progression and mortality, J Neural Trans, 253

10.1136/jnnp.52.6.773

10.1136/bmj.307.6902.469

10.2165/00003495-199855001-00004

Vajda FJ, 1978, Patterns of response to levodopa in Parkinson's disease, Clin Exp Neurol, 15, 299

10.1212/WNL.36.11.1528

van der Drift JH, 1986, 529

10.1212/WNL.37.5.826

10.1212/WNL.39.3.336

10.1212/WNL.41.5.622

10.1136/jnnp.57.9.1034

10.1136/bmj.311.7020.1602

10.1111/j.1600-0404.1996.tb00163.x

10.1111/j.1600-0404.1997.tb00101.x

10.1002/1531-8257(199907)14:4<605::AID-MDS1009>3.0.CO;2-H

10.1212/WNL.53.5.1012

10.1046/j.1468-1331.1999.650539.x

10.1056/NEJM200005183422004

McDowell FH, 1979, 475

10.1212/WNL.41.3.380

10.1002/mds.870120207

Thông tin
Thông tin xuất bản

Movement Disorders

Tập 16 Số 3

448-458

Thông tin tác giả